| 000 | 00979 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250517193606.0 | ||
| 264 | 0 | _c20181120 | |
| 008 | 201811s 0 0 eng d | ||
| 022 | _a1474-5488 | ||
| 024 | 7 |
_a10.1016/S1470-2045(17)30859-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTanimoto, Tetsuya | |
| 245 | 0 | 0 |
_aCarfilzomib for relapsed or refractory multiple myeloma. _h[electronic resource] |
| 260 |
_bThe Lancet. Oncology _c01 2018 |
||
| 300 |
_ae1 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMultiple Myeloma |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 | _aOligopeptides |
| 650 | 0 | 4 | _aProteasome Inhibitors |
| 700 | 1 | _aTsuda, Kenji | |
| 700 | 1 | _aOshima, Kumi | |
| 700 | 1 | _aMori, Jinichi | |
| 700 | 1 | _aShimmura, Hiroaki | |
| 773 | 0 |
_tThe Lancet. Oncology _gvol. 19 _gno. 1 _gp. e1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1470-2045(17)30859-8 _zAvailable from publisher's website |
| 999 |
_c27951142 _d27951142 |
||